Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Aging and Hematological Neoplasms
share announcement

Aging and Hematological Neoplasms

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 8230

Special Issue Editor

Dr. Salvatrice Mancuso

E-Mail Website
Guest Editor
Section of Hematology, Department of Health Promotion Sciences, Maternal and Infantile Care, Internal Medicine and Medical Specialties "G. D'Alessandro", University of Palermo, Palermo, Italy
Interests: lymphomagenesis; lymphomas; lymphoma and ageing

Special Issue Information

Dear Colleagues,

Most hematological neoplasms are predominantly diseases of older adults. Aging plays an important role in disease initiation and progression. Clonally restricted hematopoiesis is a common aging-associated biological state that predisposes to the development of a hematological malignancy. Potential drivers of progression from precursor states to overt neoplasia including secondary mutations in clonal cells, altered transcriptional program, marrow microenvironment inflammatory changes and immune exhaustion are also related to aging. With regard to clinical aspects, there are many challenges that we face when treating older patients with hematological malignancy. Age negatively affects survival, but elderly patients represent a heterogeneous population that varies significantly in fitness. Given the aging population and the concomitant increase in the number of older adults with cancer, the need to incorporate geriatric assessment into the care of elderly patients with hematological neoplasms is increasingly being recognized. Although significant progress has been made in recent years due to novel agents and strategies,  these patients represent a group with the highest unmet medical need. The aim of this Special Issue is to address the complex relationship between aging and hematological neoplasms, including both biological and pathogenetic aspects as well as clinical and therapeutic challenges.

Dr. Salvatrice Mancuso
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

22 pages, 714 KiB  
Review
Clinical Dilemmas in the Treatment of Elderly Patients Suffering from Hodgkin Lymphoma: A Review
by Vibor Milunović, Ida Hude, Goran Rinčić, Davor Galušić, Aron Grubešić, Marko Martinović, Nika Popović, Sunčana Divošević, Klara Brčić, Marin Međugorac, Luka Kužat, Dejan Strahija, Stefan Mrđenović, Inga Mandac Smoljanović, Delfa Radić-Krišto, Slavko Gašparov, Igor Aurer and Slobodanka Ostojić Kolonić
Biomedicines 2022, 10(11), 2917; https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines10112917 - 14 Nov 2022
Viewed by 4323
Abstract
Elderly patients make up a significant number of cases of newly diagnosed Hodgkin lymphoma. However, unlike in young patients, the outcomes of elderly patients are poor, and they are under-represented in phase III trials. Prior to treatment initiation, geriatric assessment should ideally be [...] Read more.
Elderly patients make up a significant number of cases of newly diagnosed Hodgkin lymphoma. However, unlike in young patients, the outcomes of elderly patients are poor, and they are under-represented in phase III trials. Prior to treatment initiation, geriatric assessment should ideally be performed to address the patient’s fitness and decide whether to pursue a curative or palliative approach. The ABVD regimen is poorly tolerated in unfit patients, with high treatment-related mortality. Alternative chemotherapy approaches have been explored, with mixed results obtained concerning their feasibility and toxicity in phase II trials. The introduction of brentuximab vedotin-based regimens led to a paradigm shift in first- and further-line treatment of elderly Hodgkin lymphoma patients, providing adequate disease control within a broader patient population. As far as checkpoint inhibitors are concerned, we are only just beginning to understand the role in the treatment of this population. In relapsed/refractory settings there are few options, ranging from autologous stem cell transplantation in selected patients to pembrolizumab, but unfortunately, palliative care is the most common modality. Importantly, published studies are frequently burdened with numerous biases (such as low numbers of patients, selection bias and lack of geriatric assessment), leading to low level of evidence. Furthermore, there are few ongoing studies on this topic. Thus, elderly Hodgkin lymphoma patients are hard to treat and represent an unmet need in hematologic oncology. In conclusion, treatment needs to be personalized and tailored on a case-by-case basis. In this article, we outline treatment options for elderly Hodgkin lymphoma patients. Full article
(This article belongs to the Special Issue Aging and Hematological Neoplasms)
►▼ Show Figures

Figure 1

Other

Jump to: Review

9 pages, 4714 KiB  
Case Report
Invasive Cutaneous Candidiasis, Autoimmune Hemolytic Anemia and Pancytopenia: A Challenging Scenario for Waldenström Macroglobulinemia in an Elderly Patient
by Juan Carlos Caballero, Elham Askari, Nerea Carrasco, Miguel Angel Piris, Begoña Perez de Camino, Laura Pardo, Javier Cornago, Jose Luis Lopez-Lorenzo, Pilar Llamas and Laura Solan
Biomedicines 2023, 11(4), 1007; https://0-doi-org.brum.beds.ac.uk/10.3390/biomedicines11041007 - 24 Mar 2023
Cited by 1 | Viewed by 3490
Abstract
Waldenström macroglobulinemia (WM) is a slowly progressive hematologic malignancy that usually responds rapidly to treatment. Being a lymphoplasmacytoid neoplasm, it is associated with a monoclonal IgM component, which may be associated with multiple manifestations and symptoms. We report the case of a 77-year-old [...] Read more.
Waldenström macroglobulinemia (WM) is a slowly progressive hematologic malignancy that usually responds rapidly to treatment. Being a lymphoplasmacytoid neoplasm, it is associated with a monoclonal IgM component, which may be associated with multiple manifestations and symptoms. We report the case of a 77-year-old woman diagnosed with WM following the development of severe and sudden pancytopenia associated with a cold agglutinin syndrome. In order to treat the WM and the underlying hemolysis, treatment with rituximab, corticosteroids and cyclophosphamide was started. Despite the improvement in hemolysis parameters, pancytopenia persisted, and we started a second line with ibrutinib. During treatment the patient developed an uncommon invasive fungal infection (IFI) with bone marrow granulomatosis and myelofibrosis. This case shows an unusual clinical course with a poor hematopoietic response to treatment and a large number of intercurrent complications. Full article
(This article belongs to the Special Issue Aging and Hematological Neoplasms)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop